Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Atrial Fibrillation in Obesity
NCT06499857Phase 3Recruiting
- Sponsor
- University of Chicago
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Semaglutide with Placebo (2 arms). Primary endpoints: Time to first AF event detected by routine outpatient monitoring and Change from baseline in AF burden detected by routine outpatient monitoring. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06499857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499857.